Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

licence deal

- PMLiVE

Otsuka finally gets FDA OK for kidney disease drug

Approval at last for rare disease treatment

- PMLiVE

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Foliglurax is currently in phase II testing for LID, muscle stiffness and ‘freezing’

Otsuka rewards digital health startup NeuroFlow

Mental illness tech platform wins the pharma firm's US pitch challenge

- PMLiVE

Another Alzheimer’s bust as Merck & Co stops verubecestat study

Late-stage BACE1 failure could be an ominous signal for Eli Lilly/AZ and Biogen/Eisai

- PMLiVE

Lundbeck and Otsuka start phase III for Rexulti in bipolar

Drug is also in phase II trial to treat PTSD patients

- PMLiVE

Teva poaches Lundbeck’s Schultz as new CEO

Shares in Lundbeck fall as two senior posts become vacant

- PMLiVE

Lundbeck partners with 23andMe on first-of-its-kind study

Psychiatry collaboration will combine data from genetics, cognitive tests and online surveys

- PMLiVE

IMI aims €130m at medical research’s unanswered questions

Targets for the partnership’s latest funding round including Alzheimer’s

- PMLiVE

Merck BACE inhibitor adds to litany of Alzheimer’s trial failures

Interim data shows “virtually no chance” of clinical success for verubecestat

Lundbeck partners with IBM Watson on drug research

The deal will also see it set up a new real world evidence platform

- PMLiVE

AbbVie takes anti-tau drug into phase II for Alzheimer’s

Also testing antibody in rare condition PSP, for which FDA has awarded fast-track designation

Biogen Idec building

Biogen elevates Vounatsos to top seat

US biotech’s CCO to succeed George Scangos on 6 January

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links